Rosetta Genomics to present posters on microRNA-based technologies at AACR 2010

Apr 12 2010

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research's (AACR) 101^st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010.

“One microRNA Has Prognostic Potential For Malignant Pleural Mesothelioma”

The posters will include data on Rosetta Genomics' unique microRNA-based technologies and how they may be applied to develop objective and standardized diagnostic tests for cancer.

"This cumulative body of clinical data underscores the important role microRNAs can play in diagnosing and treating a variety of cancers," noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. "We continue to build upon our scientific and clinical data to further validate the strength of our microRNA platform technologies, and demonstrate our ability to harness the power of microRNAs to advance the standard of care in diagnosing and treating cancer."

Presented posters:

1. "One microRNA Has Prognostic Potential For Malignant Pleural Mesothelioma" Tuesday, April 20 from 2:00 PM - 5:00 PM, Exhibit Hall A-C, Poster Section 7, Abstract #4053
2. "Prognostic value of microRNAs expression in diffuse large B cell lymphoma" Tuesday, April 20 from 2:00 PM - 5:00 PM, Exhibit Hall A-C, Poster Section 7, Abstract #4054
3. "microRNAs as prognostic indicators in gastric cancer" Tuesday, April 20 from 9:00 AM - 12:00 PM, Exhibit Hall A-C, Poster Section 3, Temporary Abstract #5296
4. "microRNAs as a powerful diagnostic tool for the differential diagnosis of kidney tumors" Tuesday, April 20 from 9:00 AM - 12:00 PM, Exhibit Hall A-C, Poster Section 3, Abstract #3019